BOKSLUTSKOMMUNIKÉ HELÅRET 2012 CHRONTECH PHARMA AB (PUBL)
January 25, 2013 01:00 ET
|
Fastilium Property Group AB
· Forsknings- och utvecklingskostnader 13,9 (15,2) MSEK
· Resultat efter skatt -19,7 (-20,2) MSEK
· Resultat per aktie -0,11 (-0,17) SEK
· Bolaget hade ingen nettoomsättning under perioden
...
INTERIM REPORT JANUARY-SEPTEMBER 2012 CHRONTECH PHARMA AB
October 26, 2012 01:36 ET
|
Fastilium Property Group AB
· Research and development costs amounted to SEK 10.7 (10.5) m
· The loss after tax was SEK -14.9 (-13.9) m
· Earnings per share were SEK -0.08 (-0.14)
· The company had no net sales for the...
DELÅRSRAPPORT JANUARI-SEPTEMBER 2012 CHRONTECH PHARMA AB (PUBL)
October 26, 2012 01:29 ET
|
Fastilium Property Group AB
· Forsknings- och utvecklingskostnader 10,7 (10,5) MSEK
· Resultat efter skatt -14,9 (-13,9) MSEK
· Resultat per aktie -0,08 (-0,14) SEK
· Bolaget hade ingen nettoomsättning under perioden
...
OPSONIC HAS BEEN FINANCED THROUGH A CONVERTIBLE LOAN
August 31, 2012 01:35 ET
|
Fastilium Property Group AB
During 2009 ChronTech out licensed an exclusive right to the RAS® technology to
the American company, Opsonic Therapeutics, and in return received 20% of
outstanding Opsonic stock.
Opsonic...
OPSONIC HAR FINANSIERATS MED KONVERTIBELT LÅN
August 31, 2012 01:30 ET
|
Fastilium Property Group AB
Under 2009 utlicensierade ChronTech sin RAS-teknologi till det amerikanska
bolaget Opsonic Therapeutics, vilket gav ChronTech ett 20%-igt ägande i Opsonic.
Opsonic har nu erhållit ett konvertibelt...
INTERIM REPORT JANUARY-JUNE 2012 CHRONTECH PHARMA AB
August 24, 2012 02:30 ET
|
Fastilium Property Group AB
· Research and development costs amounted to SEK 6.7 (6.8) m
· The loss after tax was SEK -9.6 (-9.0) m
· Earnings per share were SEK -0.05 (-0.11)
· The company had no net sales for the...
DELÅRSRAPPORT JANUARI-JUNI 2012 CHRONTECH PHARMA AB (PUBL)
August 24, 2012 02:20 ET
|
Fastilium Property Group AB
· Forsknings- och utvecklingskostnader 6,7 (6,8) MSEK
· Resultat efter skatt -9,6 (-9,0) MSEK
· Resultat per aktie -0,05 (-0,11) SEK
· Bolaget hade ingen nettoomsättning under perioden
·...
INTERIM REPORT JANUARY-MARCH 2012 CHRONTECH PHARMA AB
April 27, 2012 01:05 ET
|
Fastilium Property Group AB
· Research and development costs amounted to SEK 3.2 (3.8) m
· The loss
after tax was SEK -4.2 (-5.0) m
· Earnings per share were SEK -0.02 (-0.06)
· The company had no net sales for the...
DELÅRSRAPPORT JANUARI-MARS 2012 CHRONTECH PHARMA AB (PUBL)
April 27, 2012 01:00 ET
|
Fastilium Property Group AB
· Forsknings- och utvecklingskostnader 3,2 (3,8) MSEK
· Resultat efter
skatt -4,2 (-5,0) MSEK
· Resultat per aktie -0,02 (-0,06) SEK
· Bolaget
hade ingen nettoomsättning under perioden
·...
The Annual General Meeting of ChronTech Pharma AB
April 17, 2012 05:27 ET
|
Fastilium Property Group AB
The Annual General Meeting of ChronTech Pharma AB was held in Stockholm on April
16th, 2012.
Annual Report and discharge from liability
The Company's
Income Statement and Balance Sheet were adopted...